We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

woensdag 10 januari 2018

Leukemia - Table of Contents alert Volume 32 Issue 1

If you are unable to see the message below, click here to view.
Leukemia
TABLE OF CONTENTS

Volume 32, Issue 1 (January 2018)

In this issue
Review
Original Articles
Letters to the Editor

Also new
AOP
 
Sign up for e-alerts Sign up for e-alerts
Recommend to your library
Web feed
Follow on Twitter
Subscribe

Review

Top

Therapeutic targeting of CK2 in acute and chronic leukemias OPEN

F Buontempo, J A McCubrey, E Orsini, M Ruzzene, A Cappellini, A Lonetti, C Evangelisti, F Chiarini, C Evangelisti, J T Barata and A M Martelli

Leukemia 2018 32: 1-10; advance online publication, September 27, 2017; 10.1038/leu.2017.301

Abstract | Full Text

Original Articles

Top

ACUTE MYELOID LEUKEMIA

Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia OPEN

M Mingay, A Chaturvedi, M Bilenky, Q Cao, L Jackson, T Hui, M Moksa, A Heravi-Moussavi, R K Humphries, M Heuser and M Hirst

Leukemia 2018 32: 11-20; advance online publication, June 2, 2017; 10.1038/leu.2017.171

Abstract | Full Text

Long-term outcome of older patients with newly diagnosed de novo acute promyelocytic leukemia treated with ATRA plus anthracycline-based therapy

D Martínez-Cuadrón, P Montesinos, E Vellenga, T Bernal, O Salamero, A Holowiecka, S Brunet, C Gil, C Benavente, J M Ribera, M Pérez-Encinas, J De la Serna, J Esteve, V Rubio, J González-Campos, L Escoda, M E Amutio, M Arnan, J Arias, S Negri, B Lowënberg and M A Sanz on behalf of the PETHEMA, HOVON, PALG and GATLA groups

Leukemia 2018 32: 21-29; advance online publication, June 6, 2017; 10.1038/leu.2017.178

Abstract | Full Text

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia

V I Gaidzik, D Weber, P Paschka, A Kaumanns, S Krieger, A Corbacioglu, J Krönke, S Kapp-Schwoerer, D Krämer, H-A Horst, I Schmidt-Wolf, G Held, A Kündgen, M Ringhoffer, K Götze, T Kindler, W Fiedler, M Wattad, R F Schlenk, L Bullinger, V Teleanu, B Schlegelberger, F Thol, M Heuser, A Ganser, H Döhner, K Döhner and for the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG)

Leukemia 2018 32: 30-37; advance online publication, June 23, 2017; 10.1038/leu.2017.200

Abstract | Full Text

ACUTE LYMPHOBLASTIC LEUKEMIA

Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis

S J Welsh, M L Churchman, M Togni, C G Mullighan and J Hagman

Leukemia 2018 32: 38-48; advance online publication, May 30, 2017; 10.1038/leu.2017.166

Abstract | Full Text

HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia OPEN

S Tharkar-Promod, D P Johnson, S E Bennett, E M Dennis, B G Banowsky, S S Jones, J R Shearstone, S N Quayle, C Min, M Jarpe, T Mosbruger, A D Pomicter, R R Miles, W Y Chen, K N Bhalla, P A Zweidler-McKay, D C Shrieve, M W Deininger, M B Chandrasekharan and S Bhaskara

Leukemia 2018 32: 49-60; advance online publication, June 5, 2017; 10.1038/leu.2017.174

Abstract | Full Text

TCRα rearrangements identify a subgroup of NKL-deregulated adult T-ALLs associated with favorable outcome

P Villarese, C Lours, A Trinquand, S Le Noir, M Belhocine, L Lhermitte, A Cieslak, M Tesio, A Petit, M LeLorch, S Spicuglia, N Ifrah, H Dombret, A W Langerak, N Boissel, E Macintyre and V Asnafi

Leukemia 2018 32: 61-71; advance online publication, June 8, 2017; 10.1038/leu.2017.176

Abstract | Full Text

CHRONIC LYMPHOCYTIC LEUKEMIA

Aberrant splicing of the tumor suppressor CYLD promotes the development of chronic lymphocytic leukemia via sustained NF-κB signaling

M Hahn, J-P Bürckert, C A Luttenberger, S Klebow, M Hess, M Al-Maarri, M Vogt, S Reißig, M Hallek, A Wienecke-Baldacchino, T Buch, C P Muller, C P Pallasch, F T Wunderlich, A Waisman and N Hövelmeyer

Leukemia 2018 32: 72-82; advance online publication, June 1, 2017; 10.1038/leu.2017.168

Abstract | Full Text

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL OPEN

J R Brown, P Hillmen, S O’Brien, J C Barrientos, N M Reddy, S E Coutre, C S Tam, S P Mulligan, U Jaeger, P M Barr, R R Furman, T J Kipps, F Cymbalista, P Thornton, F Caligaris-Cappio, J Delgado, M Montillo, S DeVos, C Moreno, J M Pagel, T Munir, J A Burger, D Chung, J Lin, L Gau, B Chang, G Cole, E Hsu, D F James and J C Byrd

Leukemia 2018 32: 83-91; advance online publication, June 8, 2017; 10.1038/leu.2017.175

Abstract | Full Text

LYMPHOMA

An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma

A Lollies, S Hartmann, M Schneider, T Bracht, A L Weiß, J Arnolds, L Klein-Hitpass, B Sitek, M-L Hansmann, R Küppers and M A Weniger

Leukemia 2018 32: 92-101; advance online publication, June 29, 2017; 10.1038/leu.2017.203

Abstract | Full Text

MULTIPLE MYELOMA, GAMMOPATHIES

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients OPEN

V Shah, A L Sherborne, B A Walker, D C Johnson, E M Boyle, S Ellis, D B Begum, P Z Proszek, J R Jones, C Pawlyn, S Savola, M W Jenner, M T Drayson, R G Owen, R S Houlston, D A Cairns, W M Gregory, G Cook, F E Davies, G H Jackson, G J Morgan and M F Kaiser on behalf of the NCRI Haemato-oncology CSG

Leukemia 2018 32: 102-110; advance online publication, June 6, 2017; 10.1038/leu.2017.179

Abstract | Full Text

Nucleotide excision repair is a potential therapeutic target in multiple myeloma OPEN

R Szalat, M K Samur, M Fulciniti, M Lopez, P Nanjappa, A Cleynen, K Wen, S Kumar, T Perini, A S Calkins, E Reznichenko, D Chauhan, Y-T Tai, M A Shammas, K C Anderson, J-P Fermand, B Arnulf, H Avet-Loiseau, J-B Lazaro and N C Munshi

Leukemia 2018 32: 111-119; advance online publication, June 7, 2017; 10.1038/leu.2017.182

Abstract | Full Text

Integrative network analysis identifies novel drivers of pathogenesis and progression in newly diagnosed multiple myeloma

A Laganà, D Perumal, D Melnekoff, B Readhead, B A Kidd, V Leshchenko, P-Y Kuo, J Keats, M DeRome, J Yesil, D Auclair, S Lonial, A Chari, H J Cho, B Barlogie, S Jagannath, J T Dudley and S Parekh

Leukemia 2018 32: 120-130; advance online publication, June 23, 2017; 10.1038/leu.2017.197

Abstract | Full Text

Natural history of t(11;14) multiple myeloma

A Lakshman, M Alhaj Moustafa, S V Rajkumar, A Dispenzieri, M A Gertz, F K Buadi, M Q Lacy, D Dingli, A L Fonder, S R Hayman, M A Hobbs, W I Gonsalves, Y L Hwa, P Kapoor, N Leung, R S Go, Y Lin, T V Kourelis, J A Lust, S J Russell, S R Zeldenrust, R A Kyle and S K Kumar

Leukemia 2018 32: 131-138; advance online publication, June 27, 2017; 10.1038/leu.2017.204

Abstract | Full Text

CHRONIC MYELOPROLIFERATIVE NEOPLASMS

SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis OPEN

G Martinelli, M Mancini, C De Benedittis, M Rondoni, C Papayannidis, M Manfrini, M Meggendorfer, R Calogero, V Guadagnuolo, M C Fontana, L Bavaro, A Padella, E Zago, L Pagano, R Zanotti, L Scaffidi, G Specchia, F Albano, S Merante, C Elena, P Savini, D Gangemi, P Tosi, F Ciceri, G Poletti, L Riccioni, F Morigi, M Delledonne, T Haferlach, M Cavo, P Valent and S Soverini

Leukemia 2018 32: 139-148; advance online publication, June 16, 2017; 10.1038/leu.2017.183

Abstract | Full Text

Irf8 regulates the progression of myeloproliferative neoplasm-like syndrome via Mertk signaling in zebrafish

F Zhao, Y Shi, Y Huang, Y Zhan, L Zhou, Y Li, Y Wan, H Li, H Huang, H Ruan, L Luo and L Li

Leukemia 2018 32: 149-158; advance online publication, June 19, 2017; 10.1038/leu.2017.189

Abstract | Full Text

STEM CELL BIOLOGY

Base excision repair proteins couple activation-induced cytidine deaminase and endonuclease G during replication stress-induced MLL destabilization

B Gole, E Mian, M Rall and L Wiesmüller

Leukemia 2018 32: 159-167; advance online publication, June 19, 2017; 10.1038/leu.2017.191

Abstract | Full Text

STEM CELL TRANSPLANTATION

HLA-DPB1 mismatch induces a graft-versus-leukemia effect without severe acute GVHD after single-unit umbilical cord blood transplantation

T Yabe, F Azuma, K Kashiwase, K Matsumoto, T Orihara, H Yabe, S Kato, K Kato, S Kai, T Mori, S Morishima, M Satake, M Takanashi, K Nakajima, Y Morishima and on behalf of Japanese Cord Blood Transplantation Histocompatibility Research Group

Leukemia 2018 32: 168-175; advance online publication, June 27, 2017; 10.1038/leu.2017.202

Abstract | Full Text

MOLECULAR TARGETS FOR THERAPY

Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma

Q Wang, Y Lu, R Li, Y Jiang, Y Zheng, J Qian, E Bi, C Zheng, J Hou, S Wang and Q Yi

Leukemia 2018 32: 176-183; advance online publication, June 19, 2017; 10.1038/leu.2017.193

Abstract | Full Text

TRANSCRIPTIONAL CONTROL AND SIGNAL TRANSDUCTION, CELL CYCLE

PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells

L Sun, Y Shi, G Wang, X Wang, S Zeng, S E Dunn, G D Fairn, Y-J Li and D E Spaner

Leukemia 2018 32: 184-193; advance online publication, May 30, 2017; 10.1038/leu.2017.162

Abstract | Full Text

Differential effects on gene transcription and hematopoietic differentiation correlate with GATA2 mutant disease phenotypes OPEN

C-E Chong, P Venugopal, P H Stokes, Y K Lee, P J Brautigan, D T O Yeung, M Babic, G A Engler, S W Lane, M Klingler-Hoffmann, J M Matthews, R J D'Andrea, A L Brown, C N Hahn and H S Scott

Leukemia 2018 32: 194-202; advance online publication, June 23, 2017; 10.1038/leu.2017.196

Abstract | Full Text

SHP2 is required for BCR-ABL1-induced hematologic neoplasia

S Gu, A Sayad, G Chan, W Yang, Z Lu, C Virtanen, R A Van Etten and B G Neel

Leukemia 2018 32: 203-213; advance online publication, August 14, 2017; 10.1038/leu.2017.250

Abstract | Full Text

S1PR1 drives a feedforward signalling loop to regulate BATF3 and the transcriptional programme of Hodgkin lymphoma cells OPEN

K Vrzalikova, M Ibrahim, M Vockerodt, T Perry, S Margielewska, L Lupino, E Nagy, E Soilleux, D Liebelt, R Hollows, A Last, G Reynolds, M Abdullah, H Curley, M Care, D Krappmann, R Tooze, J Allegood, S Spiegel, W Wei, C B J Woodman and P G Murray

Leukemia 2018 32: 214-223; advance online publication, September 7, 2017; 10.1038/leu.2017.275

Abstract | Full Text

Letters to the Editor

Top

RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo

N Jyotsana, A Sharma, A Chaturvedi, M Scherr, F Kuchenbauer, L Sajti, A Barchanski, R Lindner, F Noyan, K-W Sühs, D Grote-Koska, K Brand, H-P Vornlocher, M Stanulla, B Bornhauser, J-P Bourquin, M Eder, F Thol, A Ganser, R K Humphries, E Ramsay, P Cullis and M Heuser

Leukemia 2018 32: 224-226; advance online publication, August 22, 2017; 10.1038/leu.2017.269

Full Text

Prevalence of somatic mutations in patients with aplastic anemia using peripheral blood cfDNA as compared with BM OPEN

A Albitar, D Townsley, W Ma, I De Dios, V Funari, N S Young and M Albitar

Leukemia 2018 32: 227-229; advance online publication, August 23, 2017; 10.1038/leu.2017.271

Full Text

Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy

K R Kelly, C M Espitia, W Zhao, K Wu, V Visconte, F Anwer, C M Calton, J S Carew and S T Nawrocki

Leukemia 2018 32: 230-233; advance online publication, August 23, 2017; 10.1038/leu.2017.272

Full Text

Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL OPEN

K Brazdilova, K Plevova, H Skuhrova Francova, H Kockova, M Borsky, V Bikos, J Malcikova, A Oltova, J Kotaskova, B Tichy, Y Brychtova, J Mayer, M Doubek and S Pospisilova

Leukemia 2018 32: 234-236; advance online publication, August 29, 2017; 10.1038/leu.2017.274

Full Text

Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia

M Waibel, S J Vervoort, I Y Kong, S Heinzel, K M Ramsbottom, B P Martin, E D Hawkins and R W Johnstone

Leukemia 2018 32: 237-241; advance online publication, September 15, 2017; 10.1038/leu.2017.282

Full Text

Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse

P Boddu, J Jorgensen, H Kantarjian, G Borthakur, T Kadia, N Daver, Y Alvarado, N Pemmaraju, P Bose, K Naqvi, M Yilmaz, S Pierce, M Brandt, C D DiNardo, E J Jabbour, M Konopleva, G Garcia-Manero, J Cortes and F Ravandi

Leukemia 2018 32: 241-244; advance online publication, September 18, 2017; 10.1038/leu.2017.285

Full Text

Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials

C Piette, S Suciu, E Clappier, Y Bertrand, S Drunat, S Girard, K Yakouben, G Plat, N Dastugue, F Mazingue, N Grardel, N van Roy, A Uyttebroeck, V Costa, O Minckes, N Sirvent, P Simon, P Lutz, A Ferster, C Pluchart, M Poirée, C Freycon, M-F Dresse, F Millot, C Chantrain, J van der Werff ten Bosch, K Norga, C Gilotay, P-S Rohrlich, Y Benoit and H Cavé

Leukemia 2018 32: 244-248; advance online publication, September 19, 2017; 10.1038/leu.2017.289

Full Text

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature